Servicio de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, España.
Servicio de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, España.
Actas Dermosifiliogr. 2022 Apr;113(4):376-387. doi: 10.1016/j.ad.2021.09.005. Epub 2021 Dec 31.
Immune checkpoint inhibitors (ICIs) have significantly advanced the treatment of cancer. They are not, however, free of adverse effects. These effects are called immune-related adverse events (irAEs) and often involve the skin. Most of the information on cutaneous irAEs comes from clinical practice. We therefore conducted a thorough review of the characteristics of cutaneous irAEs, recommendations for treatment, and their association with prognosis. The most common events are exanthema, pruritus, vitiligo, and hair loss, although ICIs can cause a wide range of cutaneous dermatoses. The reported association observed between certain reactions and a favorable response to cancer treatment should be interpreted with caution. Dermatologists should be involved in the multidisciplinary care of patients being treated with ICIs as they have an essential role in the diagnosis and treatment of cutaneous irAEs.
免疫检查点抑制剂 (ICIs) 显著提高了癌症的治疗效果。然而，它们并非没有不良反应。这些作用被称为免疫相关不良反应 (irAEs)，常涉及皮肤。大多数关于皮肤 irAEs 的信息来自临床实践。因此，我们对皮肤 irAEs 的特征、治疗建议及其与预后的关系进行了全面回顾。最常见的事件是皮疹、瘙痒、白癜风和脱发，尽管 ICI 可引起广泛的皮肤疾病。报告的某些反应与癌症治疗的有利反应之间的关联应谨慎解释。皮肤科医生应参与接受 ICI 治疗的患者的多学科护理，因为他们在诊断和治疗皮肤 irAEs 方面发挥着重要作用。
